Invis Tablets

Adult dose

Usually, regardless of meals, 2 tablets are taken orally 2 times a day before morning and bedtime. 1) Gastric and Duodenal Ulcers: 2 tablets are administered 2 times a day or 4 tablets once a day before bedtime. Especially for patients with duodenal ulcers, administering 4 tablets 2 times a day before morning and bedtime can achieve a higher treatment rate. Ulcer caused by the administration of non-steroidal anti-inflammatory drugs or for preventive combination therapy against gastric and duodenal ulcer occurrence due to long-term use of non-steroidal anti-inflammatory drugs involves the same dosage. Generally, conditions caused by the administration of non-steroidal anti-inflammatory drugs can heal within 8 weeks, although healing time may occasionally be prolonged depending on the patient. For patients with recurrent ulcers who exhibited excellent results during short-term therapy, a maintenance dose of 2 tablets once a day before bedtime is advised. 2) Gastroesophageal Reflux: Administer 2 tablets 2 times a day for 8 weeks or 4 tablets once a day before bedtime. However, for severe gastroesophageal reflux patients, the dosage may be increased to 4 tablets 4 times a day. 3) Zollinger-Ellison Syndrome: Initiate treatment with an initial dose of 2 tablets 3 times a day, with possible increases as needed. In severe conditions, a daily dose of 6 g of ranitidine may be administered according to the physician's instructions. 4) Peptic ulcer, acute stress ulcer, and upper gastrointestinal bleeding due to acute mucosal lesions: Once oral administration becomes possible, transition from injection to oral administration of 2 tablets 2 times a day. 5) Pre-anesthetic dosing (to prevent Mendelson syndrome): Administer 2 tablets 2 hours before anesthesia induction. In this case, it is also good to administer 2 tablets the night before surgery.

This medication should not be used in patients with impaired kidney function or patients undergoing dialysis. It should not be administered to individuals allergic to this drug or its components. Patients with a history of acute porphyria should be cautious as this medication may exacerbate symptoms. It is contraindicated in patients who have undergone upper gastrointestinal tract surgery, pregnant women or those who may become pregnant, and premature or newborn infants. Patients on a potassium-restricted diet should also avoid this medication. Caution is warranted in patients with liver dysfunction, previous drug allergies, elderly patients, and those with a history of kidney impairment when using this medication. Special care is required if taken with non-steroidal anti-inflammatory drugs (NSAIDs), and regular monitoring is essential. It may mask symptoms of gastric cancer, thus gastric ulcer patients or middle-aged and older patients with new or changing dyspeptic symptoms should confirm malignancy status before administration. Patients with gastric or duodenal ulcers infected with Helicobacter pylori require eradication therapy. In critically ill patients or those with hypophosphatemia and swallowing difficulties, this medication should be given cautiously due to the risk of side effects. Long-term use of this medication is not recommended, and if no therapeutic effect is observed, switching to another drug is advisable. Elderly patients or those with chronic lung disease, diabetes, or weakened immunity are at increased risk of pneumonia while taking this medication. If dizziness or drowsiness occurs during use, operating vehicles or heavy machinery should be avoided. This medication may interact with other drugs, so it is essential to inform healthcare providers of all medications being taken, especially anticoagulants, for careful monitoring of blood coagulation status. Pregnant or breastfeeding women should not use this medication, and safety in children has not been established, so its use is not recommended. In cases of overdose, measures such as vomiting or gastric lavage may be necessary, and removal can be achieved by blood dialysis if required. This drug may reduce gastric acid secretion and promote bacterial growth in the gastrointestinal tract, so long-term use may necessitate ophthalmologic examinations.

Serious side effects

• Hives
• angioedema
• shock
• anaphylactic shock
• severe swelling (edema)
• chest tightness
• difficulty breathing
• severe allergic reactions
• angioedema
• vasculitis

Mild side effects

• Skin rash
• hives
• angioedema
• fever
• bronchospasm
• hypotension
• chest pain
• granulocytopenia
• leukopenia
• thrombocytopenia

This medication should be stored in a tightly closed container to prevent exposure to air and moisture, and it is advisable to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage can help maintain the drug’s effectiveness.

Appearance

White, round, film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle